SEARCH

SEARCH BY CITATION

References

  • 1
    Smith CM. Liver transplantation in the United States: A report from the UNOS Liver Transplant Registry. Clin Transpl 1999:2334.
  • 2
    Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplantation–associated risk factors and outcome. Transplantation 1992; 54:821824.
  • 3
    Klintmalm GB, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989; 10:978985.
  • 4
    Starzl TE, Koep LJ, Halgrimson C, Hood J, Schroter GP, Porter KA, Weil R 3rd. Fifteen years of clinical liver transplantation. Gastroenterology 1979; 77:375378.
  • 5
    Berlakovich GA, Rockenschaub S, Taucher S, Kaserer K, Muhlbacher F, Steiniger R. Underlying disease as a predictor for rejection after liver transplantation. Arch Surg 1998; 133:167172.
  • 6
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:11101115.
  • 7
    European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344:423428.
  • 8
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7:442450.
  • 9
    Greig PD, Grant DR, Kneteman NR, McAlister VC, Scudamore CH, Roy AF, et al. Long-term results of early steroid withdrawal following liver transplantation [abstract]. Am J Transpl 2001; 1(suppl 1):418A.
  • 10
    Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340:876877.
  • 11
    Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63:243249.
  • 12
    Yoshida EM, Shackleton CR, Erb SR, Mori LM, Ford JA, Eggen H, et al. Late acute rejection occurring in liver allograft recipients. Can J Gastroenterol 1996; 10:376380.
  • 13
    Samuel D, Gugenheim J, Canon C, Saliba F, Bismuth H. Use of OKT3 for late acute rejection in liver transplantation. Transplant Proc 1990; 22:17671768.
  • 14
    Mor E, Solomon H, Gibbs JF, Holman MJ, Goldstein RM, Husberg BS, et al. Acute cellular rejection following liver transplantation: Clinical pathologic features and effect on outcome. Semin Liver Dis 1992; 12:2840.
  • 15
    Farges O, Sabila F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H. Incidence of rejection and infection after liver transplantation as a function of the primary disease: Possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996; 23:240248.
  • 16
    Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, Klintmalm G, et al. Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation 1988; 46:372377.
  • 17
    O'Grady JG, Alexander GJ, Sutherland S, Donaldson PR, Harvey F, Portmann B, Calne RY. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988; 2:302305.
  • 18
    Howard TK, Klintmalm GB, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 1990; 49:103107.
  • 19
    Nikaein A, Backman L, Jennings L, Levy MF, Goldstein R, Gonwa T, et al. HLA compatibility and liver transplantation outcome. Improved patient survival and cross-matching. Transplantation 1994; 58:786792.
  • 20
    Demetris AJ, Seaberg EC, Batts KP, Ferrell LD, Ludwig J, Markin RS, et al. Reliability and predictive value of the NIDDK liver transplant database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 1995; 21:408416.
  • 21
    Hubscher S. Histologic findings in liver allograft rejection—New insights into the pathogenesis of hepatocellular damage in liver allografts. Histopathology 1991; 18:377383.
  • 22
    Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60:10981103.
  • 23
    Feray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear cells without concomitant liver infection: The liver transplantation model. Transplantation 1990; 49:11551158.
  • 24
    Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000; 6:553561.
  • 25
    Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, McMichael JP, et al. The Pittsburgh randomized trial of tacrolimus compared with cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183:117125.
  • 26
    Dousset B, Hubscher SG, Padbury RT, Gunson BK, Buckels JA, Mayer AD, et al: Acute liver allograft rejection—Is treatment always necessary? Transplantation 1993; 55:529534.
  • 27
    Backman L, Gibbs J, Levy M, McMillan R, Holman M, Husberg B, et al. Causes of late graft loss after liver transplantation. Transplantation 1993; 55:10781082.